Identification of comparable biomarkers in humans and validated animal models will facilitate pre-clinical to clinical therapeutic pipelines to treat neurodevelopmental disorders. Fragile X Syndrome (FXS) is a leading known genetic cause of intellectual disability with symptoms that include increased anxiety, social and sensory processing deficits. Recent EEG studies in humans with FXS have identified neural oscillation deficits that include enhanced resting state gamma power and reduced inter-trial coherence of sound evoked gamma oscillations. To determine if analogous phenotypes are present in an animal model of FXS, we recorded EEGs in awake, freely moving Fmr1 knock out (KO) mice using similar stimuli as in the human studies. We report remarkably similar neural oscillation phenotypes in the Fmr1 KO mouse including enhanced resting state gamma power and reduced evoked gamma synchronization. The gamma band inter-trial coherence of neural response was reduced in both auditory and frontal cortex of Fmr1 KO mice stimulated with a sound whose envelope was modulated from 1 to 100 Hz, similar to that seen in humans with FXS. These deficits suggest a form of enhanced 'resting state noise' that interferes with the ability of the circuit to mount a synchronized response to sensory input, predicting specific sensory and cognitive deficits in FXS. The abnormal gamma oscillations are consistent with parvalbumin neuron and perineuronal net deficits seen in the Fmr1 KO mouse auditory cortex indicating that the EEG biomarkers are not only clinically relevant, but could also be used to probe cellular and circuit mechanisms of sensory hypersensitivity in FXS.
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Introduction
Fragile X Syndrome (FXS) is the most common genetic cause of intellectual disability with symptoms that overlap with autism spectrum disorders (ASD, Crawford et al., 2001) . FXS is caused by a mutation in the Fragile X Mental Retardation 1 (Fmr1) gene and downregulation of Fragile X Mental Retardation Protein (FMRP, Yu et al., 1991) . FMRP is an RNA binding protein that regulates synaptic function through effects on protein translation (Darnell et al., 2011) . Symptoms associated with FXS include increased anxiety, repetitive behaviors, social communication deficits, delayed language development and abnormal sensory processing (Wisniewski et al., 1991; Abbeduto and Hagerman, 1997; Miller et al., 1999; Musumeci et al., 1999; Roberts et al., 2001; Sabaratnam et al., 2001; Berry-Kravis, 2002; Hagerman and Hagerman, 2002; Hagerman et al., 2009; Van der Molen et al., 2010; Sinclair et al., 2017) . Abnormal sensory processing in FXS includes hypersensitivity and reduced habituation to repeated sensory stimuli (Castren et al., 2003; Schneider et al., 2013) . These symptoms that affect multiple sensory systems are seen early in development and may lead to increased anxiety and cognitive deficits.
Basic sensory processing mechanisms, in general, are more conserved across species compared to circuits shaping complex social and cognitive behaviors, providing an opportunity to better understand the pathophysiology of FXS/ASD at a neural circuit level. Auditory processing deficits are common in both humans with FXS (Castren et al., 2003; Schneider et al., 2013; Van der Molen and Van der Molen, 2013; Ethridge et al., 2016) and Fmr1 knockout (KO) mice (Rotschafer and Razak, 2013, 2014; Lovelace et al., 2016; Wen et al., 2017) , the mouse model of FXS (Bakker et al., 1994; Bernardet and Crusio, 2006) . Recent EEG recordings from humans showed altered cortical oscillatory activity that may contribute to sensory hypersensitivity and social communication deficits in FXS (Ethridge et al., 2017; Wang et al., 2017) . Gamma frequency power was enhanced in humans with FXS compared to healthy controls (Wang et al., 2017 
